Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and characterization capability with Locus’s CRISPR-based synthetic biology platform and clinical development team creates a combined entity that is rapidly developing products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome. Terms of the deal are undisclosed.